印度的醫藥品及生物科技產業的市場機會

印度的醫藥品及生物科技產業的市場機會 是由出版商Pharmalicensing Ltd.在2006年04月所出版的。 這份英文市場調查報告書包含111 pages 價格從美金1200起跳。

簡介

目錄

Abstract

India is an increasingly attractive destination for R&D activities in the pharmaceutical and biotechnology industry. Being an emerging market, companies face a number of unique hurdles before entering this lucrative region.

The report provides an overview of the Indian pharma and biotech market, and answers the following key questions:

• Who are the key players in the Indian pharmaceutical market?
• How has the Indian regulatory environment changed?
• What R&D collaborative opportunities are available?
• How can companies engage with India for collaboration?
• What are the leading R&D companies in India doing in collaborative R&D?

Readers will gain an analysis of the regulatory environment, insights into collaborative opportunities and detailed information on the key companies, clusters and government initiatives.

This report is a valuable resource for use by all those developing company strategy and direction in this key emerging market.

'India: Pharmaceutical and biotechnology opportunities' is based on the December 2004 report 'India: The emerging R&D collaborative opportunity'. The new report includes additional sections on the Indian Patents Act 2005, the Indian pharmaceutical policy, an overview of Department of Biotechnology initiatives, including details of biotechnology parks, and an all-new set of profiles on life science research institutes.

The profiles section of 'India: Pharmaceutical and biotechnology opportunities' contains updated profiles and contact details on key companies.

Table of Contents

1. Global collaborative R&D trends

• 1.1. Falling R&D productivity
  • 1.1.1. Strategies adopted by global pharmaceutical companies to counter falling R&D productivity
• 1.2. Look East trend

2. The Indian pharmaceutical industry

• 2.1. Overview
• 2.2. Market assessment
• 2.3. Key players in the Indian pharmaceutical market

3. An analysis of the regulatory environment and its implications for R&D

• 3.1. Regulation in the Indian pharmaceutical industry: A historical perspective
• 3.2. The changing regulatory environment in India-Advantage R&D
• 3.3. An analysis of India's changing regulatory framework
  • 3.3.1. Indian Patent Act, 1970
  • 3.3.2. Patents Amendment Act, 2002
  • 3.3.3. The Patents Amendment Ordinance, 2004
  • 3.3.4. Indian Patents (Amendment) Act, 2005
  • 3.3.5. New pharmaceutical policy (2006): Focus on R&D
    • 3.3.5.1. Definitions of R&D
    • 3.3.5.2. Technology upgrade funding
• 3.4. Response of MNCs to the changing regulatory environment
• 3.5. Implications for the Indian pharmaceutical industry
  • 3.5.1. Collaborative and contract research and development
  • 3.5.2. In- and out-licensing innovations

4. Collaborative R&D opportunities in India

• 4.1. Overview
• 4.2. Engagement models for licensing/purchasing innovation
• 4.3. Engagement models for contracting research services
• 4.4. NCE and NDDS research
• 4.5. Biopharma & drug discovery
  • 4.5.1. Indian biopharma industry
    • 4.5.1.1. Market size estimates: Indian biopharma industry
    • 4.5.1.2. Indian biopharma industry: Vaccines segment
    • 4.5.1.3. Indian biopharma industry: Therapeutics segment
    • 4.5.1.4. Indian biopharma industry: Diagnostics segment
  • 4.5.2. Drug discovery services
  • 4.5.3. Indian biotechnology: Initiatives by the Department of Biotechnology
    • 4.5.3.1. National Biotechnology Development Strategy
      • 4.5.3.1.1. Fiscal and trade policy initiatives
      • 4.5.3.1.2. Financial incentives
      • 4.5.3.1.3. Biotechnology parks
      • 4.5.3.1.4. Regulatory mechanisms
      • 4.5.3.1.5. Create a cadre of resource persons
      • 4.5.3.1.6. Empowering a judiciary
      • 4.5.3.1.7. Industrial mechanisms for strengthening public trust
      • 4.5.3.1.8. Single window
      • 4.5.3.1.9. Innovation
      • 4.5.3.1.10. Strengthening technology transfer capacity
      • 4.5.3.1.11 National Task Force on Education & Training
      • 4.5.3.1.12 Needs assessment
    • 4.5.3.2. Stem cell research policy
  • 4.5.4. Major recent developments in biotechnology
• 4.6. Bioinformatics.
  • 4.6.1. Market size estimates of Indian bioinformatics industry
  • 4.6.2. Bioinformatics companies in India
  • 4.6.3. Bioinformatics policy of India
  • 4.6.4. Major recent developments in bioinformatics
• 4.7. Clinical research
  • 4.7.1. Market size estimates of the Indian clinical research industry
  • 4.7.2. Clinical trials: MNC focus on India
  • 4.7.3. Government initiatives to boost clinical research in India
  • 4.7.4. Outsourcing clinical data management to India
    • 4.7.4.1. CROs
    • 4.7.4.2. IT-pharmaceutical ventures
    • 4.7.4.3. Other IT/ITES companies' bio-initiatives

5. Conclusions

6. Company profiles

• 6.1. NCE/NDDS
  • 6.1.1. Dr Reddy's Laboratories Limited
    • 6.1.1.1. Overview
    • 6.1.1.2. R&D focus
    • 6.1.1.3. Financials
    • 6.1.1.4. Contact information
  • 6.1.2. Glenmark Pharmaceuticals Ltd
    • 6.1.2.1. Overview
    • 6.1.2.2. R&D focus
    • 6.1.2.3. Financials
    • 6.1.2.4. Contact information
  • 6.1.3. Lupin Limited
    • 6.1.3.1. Overview
    • 6.1.3.2. R&D focus
    • 6.1.3.3. Financials
    • 6.1.3.4. Contact information
  • 6.1.4. Nicholas Piramal India Limited
    • 6.1.4.1. Overview
    • 6.1.4.2. R&D focus
    • 6.1.4.3. R&D collaborations
    • 6.1.4.4. Financials
    • 6.1.4.5. Contact information
  • 6.1.5. Ranbaxy Laboratories Limited
    • 6.1.5.1. Overview
    • 6.1.5.2. R&D focus
    • 6.1.5.3. Financials
    • 6.1.5.4. Contact information
  • 6.1.6.Wockhardt Limited
    • 6.1.6.1. Overview
    • 6.1.6.2. R&D focus
    • 6.1.6.3. Financials
    • 6.1.6.4. Contact information
  • 6.1.7. Zydus Cadila
    • 6.1.7.1. Overview
    • 6.1.7.2. R&D focus
    • 6.1.7.3. Financials
    • 6.1.7.4. Contact information
• 6.2. Bioinformatics
  • 6.2.1. Avestha Gengraine Technologies Pvt. Ltd.
    • 6.2.1.1. Overview
    • 6.2.1.2. Products and services
    • 6.2.1.3. Customer deals
    • 6.2.1.4. Contact information
  • 6.2.2. Jubilant Biosys Ltd
    • 6.2.2.1. Overview
    • 6.2.2.2. Products and services
    • 6.2.2.3. Customer deals
    • 6.2.2.4. Contact information
  • 6.2.3. Molecular Connections Private Limited
    • 6.2.3.1. Overview
    • 6.2.3.2. Products and services
    • 6.2.3.3. Customer deals
    • 6.2.3.4. Contact information
  • 6.2.4. Ocimum Biosolutions Ltd
    • 6.2.4.1. Overview
    • 6.2.4.2. Products and services
    • 6.2.4.3. Customer deals
    • 6.2.4.4. Contact information
  • 6.2.5. Strand Genomics
    • 6.2.5.1. Overview
    • 6.2.5.2. Products and services
    • 6.2.5.3. Customer deals
    • 6.2.5.4. Contact information
  • 6.2.6. SysArris Software Pvt. Ltd
    • 6.2.6.1. Overview
    • 6.2.6.2. Products and services
    • 6.2.6.3. Customer deals
    • 6.2.6.4. Contact information
  • 6.2.7. Bigtec Private Ltd.
    • 6.2.7.1. Overview
    • 6.2.7.2. Products and services
    • 6.2.7.3. Customer deals
    • 6.2.7.4. Contact information
  • 6.2.8. LabVantage Solutions Private Ltd
    • 6.2.8.1. Overview
    • 6.2.8.2. Products and services
    • 6.2.8.3. Customer deals
    • 6.2.8.4. Contact information
• 6.3. Biopharma & drug discovery services
  • 6.3.1. Aurigene Discovery Technologies Limited
    • 6.3.1.1. Overview
    • 6.3.1.2. Products and services
    • 6.3.1.3. Contact information
  • 6.3.2. Syngene International Private Limited
    • 6.3.2.1. Overview
    • 6.3.2.2. Products and services
    • 6.3.2.3. Customer deals
    • 6.3.2.4. Contact information
  • 6.3.3. Reliance Research and Development Services
    • 6.3.3.1. Overview
    • 6.3.3.2. Products and services
    • 6.3.3.3. Contact information
  • 6.3.4. Reliance Life Sciences
    • 6.3.4.1. Overview
    • 6.3.4.2. Products and services
    • 6.3.4.3. Contact information
• 6.4. Clinical Research
  • 6.4.1. Clinigene International Private Limited
    • 6.4.1.1. Overview
    • 6.4.1.2. Products and services
    • 6.4.1.3. Contact information
  • 6.4.2. iGATE Clinical Research International
    • 6.4.2.1. Overview
    • 6.4.2.2. Products and services
    • 6.4.2.3. Contact information
  • 6.4.3. SIRO Clinpharm Pvt. Ltd.
    • 6.4.3.1. Overview
    • 6.4.3.2. Products and services
    • 6.4.3.3. Contact information
  • 6.4.4. Wellquest CRO
    • 6.4.4.1. Overview
    • 6.4.4.2. Products and services
    • 6.4.4.3. Contact information
  • 6.4.5. Reliance Clinical Research Services
    • 6.4.5.1. Overview
    • 6.4.5.2. Products and services
    • 6.4.5.3. Contact information
  • 6.4.6. ClinTec International
    • 6.4.6.1. Overview
    • 6.4.6.2. Products and services
    • 6.4.6.3. Contact information
  • 6.4.7. Quintiles India
    • 6.4.7.1. Overview
    • 6.4.7.2. Products and services
    • 6.4.7.3. Contact information

7. Life science research institute profiles

• 7.1. Central Drug Research Institute
  • 7.1.1. Overview
  • 7.1.2. R&D focus
  • 7.1.3. R&D expertise and technical facilities
  • 7.1.4. Collaborative opportunities
  • 7.1.5. Products and technologies developed
    • 7.1.5.1. Technologies developed
  • 7.1.6. Pharmaceutical and biotechnology opportunities
  • 7.1.7. Contact information
• 7.2. Indian Institute of Chemical Technology
  • 7.2.1. Overview
  • 7.2.2. R&D focus
  • 7.2.3. R&D expertise and technical facilities
  • 7.2.4. Collaborative opportunities
  • 7.2.5. Products and technologies developed
  • 7.2.6. Key collaborations
  • 7.2.7. Contact information
• 7.3. National Chemical Laboratory
  • 7.3.1. Overview
  • 7.3.2. R&D focus
  • 7.3.3. R&D expertise and technical facilities
  • 7.3.4. Collaborative opportunities
  • 7.3.5. Key collaborations
  • 7.3.6. Contact information
• 7.4. Center for Cellular and Molecular Biology
  • 7.4.1. Overview
  • 7.4.2. R&D focus
  • 7.4.3. R&D expertise and technical facilities
  • 7.4.4. Collaborative opportunities
  • 7.4.5. Products and technologies developed
  • 7.4.6. Key collaborations
  • 7.4.7. Contact information
• 7.5. Institute of Microbial Technology
  • 7.5.1. Overview
  • 7.5.2. R&D focus
  • 7.5.3. R&D expertise and technical facilities
  • 7.5.4. Collaborative opportunities
  • 7.5.5. Products and technologies developed
  • 7.5.6. Key collaborations
  • 7.5.7. Contact information

8. Indian biotechnology: Regional Government initiatives

• 8.1. Orissa State (Eastern India)
  • 8.1.1. Orissa biotechnology parks
• 8.2. West Bengal State (Eastern India)
• 8.3. Gujarat State (Western India)
  • 8.3.1. International Pharma & Biotech Park, Ahmedabad
  • 8.3.1.1. Contact information
  • 8.3.2. Biotechnology park, Vadodra
• 8.4. Maharashtra State (Western India)
  • 8.4.1. International Biotech Park, Pune
    • 8.4.1.1. Contact information
  • 8.4.2. Jalna Agri Biotech Park, Jalna
• 8.5. Punjab State (Northern India)
  • 8.5.1. Punjab Biotech Park, Derabassi, near Chandigarh
    • 8.5.1.1. Contact information
  • 8.5.2. Other initiatives
• 8.6. Haryana State (Northern India)
• 8.7. Himachal Pradesh State (Northern India)
  • 8.7.1. Biotech parks
• 8.8. Rajasthan State (Northern India)
  • 8.8.1. Biotechnology park at Sitapura-Jaipur
    • 8.8.1.1. Contact information
  • 8.8.2. Biotechnology park at Boranada, Jodhpur
  • 8.8.3. Biotechnology park at Bhiwadi, Alwar
• 8.9. Uttar Pradesh State (Northern India
  • 8.9.1. Lucknow biotechnology park, Lucknow
    • 8.9.1.1. Contact information
  • 8.9.2. Biotech City, NOIDA
• 8.10. Uttaranchal State (Northern India
  • 8.10.1. Biotech park, Pantnagar
• 8.11. Madhya Pradesh State (Central India
• 8.12. Karnataka State (Southern India
  • 8.12.1. Bangalore biotechnology park (Bangalore Helix)
    • 8.12.1.1. Contact information
• 8.13. Kerala State (Southern India)
  • 8.13.1. KINFRA biotech park, Kalamassery
    • 8.13.1.1. Contact information
  • 8.13.2. KINFRA biotechnology park, Trivandrum
• 8.14. Andhra Pradesh State (Southern India)
  • 8.14.1. ICICI Knowledge Park, Turkapally
  • 8.14.2. Shapoorji Pallonji Biotech Park, Genome Valley, Hyderabad
    • 8.14.2.1. Contact information
• 8.15. Tamil Nadu State (Southern India)
  • 8.15.1. TICEL Bio Park
    • 8.15.1.1. Contact information
  • 8.15.2. Mahindra Industrial Park, Mahindra City
    • 8.15.1.2. Contact information

9. Appendices

• 9.1. References
• 9.2. References
• 9.3. Abbreviations
• 9.4. Glossary
• 9.5. Author biographies
  • 9.5.1. Siraj Dhanani
  • 9.5.2. Amit Sadana
  • 9.5.3. Ashish Malik
  • 9.5.4. PharmARC

相關商品

製藥企業相關市場調查報告書

膀胱癌相關的各種合作趨勢:2007-2012年
Bladder Cancer Partnering 2007-2012
價格 : US $ 995
出版日期 : 2012年05月

腦瘤相關的各種合作趨勢:2007-2012年
Brain Cancer Partnering 2007-2012
價格 : US $ 995
出版日期 : 2012年05月

乳癌相關的各種合作趨勢:2007-2012年
Breast Cancer Partnering 2007-2012
價格 : US $ 1695
出版日期 : 2012年05月

Pharmalicensing Ltd.發行的製藥相關市場調查報告書

藥品事業發展授權合約（第3版）

The Licensing Agreement in Pharmaceutical Business Development (3rd Edition)

價格 : US $ 995

出版日期 : 2007年07月

中國的藥品市場：策略性機會分析

The Chinese Pharmaceutical Market: A strategic opportunity analysis

價格 : US $ 1200

出版日期 : 2007年01月

新藥早期研發階段及新藥開發階段的企業聯盟

Early Stage and Discovery Deals: Strategy, Structure and Payment Terms 2nd Edition

價格 : US $ 2695

出版日期 : 2006年12月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!